Download MendeleyDiscovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design.
Lee, K.L., Ambler, C.M., Anderson, D.R., Boscoe, B.P., Bree, A.G., Brodfuehrer, J.I., Chang, J.S., Choi, C., Chung, S., Curran, K.J., Day, J.E., Dehnhardt, C.M., Dower, K., Drozda, S.E., Frisbie, R.K., Gavrin, L.K., Goldberg, J.A., Han, S., Hegen, M., Hepworth, D., Hope, H.R., Kamtekar, S., Kilty, I.C., Lee, A., Lin, L.L., Lovering, F.E., Lowe, M.D., Mathias, J.P., Morgan, H.M., Murphy, E.A., Papaioannou, N., Patny, A., Pierce, B.S., Rao, V.R., Saiah, E., Samardjiev, I.J., Samas, B.M., Shen, M.W.H., Shin, J.H., Soutter, H.H., Strohbach, J.W., Symanowicz, P.T., Thomason, J.R., Trzupek, J.D., Vargas, R., Vincent, F., Yan, J., Zapf, C.W., Wright, S.W.(2017) J Med Chem 60: 5521-5542
- PubMed: 28498658 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.7b00231
- Primary Citation Related Structures:
5UIQ, 5UIR, 5UIS, 5UIT, 5UIU - PubMed Abstract:
Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays. The medicinal chemistry effort featured the judicious placement of lipophilicity, informed by co-crystal structures with IRAK4 and optimization of ADME properties to deliver clinical candidate PF-06650833 (compound 40). This compound displays a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.
- Worldwide Medicinal Chemistry, Pfizer Inc. , 1070 Science Center Drive, San Diego, California 92121, United States.
Organizational Affiliation:
